Astrazeneca PLC (NYSE:AZN) was the recipient of unusually large options trading on Wednesday. Stock investors bought 8,259 put options on the stock. This is an increase of approximately 1,510% compared to the typical volume of 513 put options.

Astrazeneca PLC (NYSE AZN) opened at $34.48 on Friday. The firm has a market capitalization of $86.36 billion, a PE ratio of 7.77, a P/E/G ratio of 2.73 and a beta of 0.75. The company has a quick ratio of 0.73, a current ratio of 0.91 and a debt-to-equity ratio of 1.09.

Several large investors have recently bought and sold shares of the stock. Fisher Asset Management LLC lifted its holdings in shares of Astrazeneca PLC by 4.7% during the 3rd quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after acquiring an additional 519,717 shares in the last quarter. BlackRock Inc. lifted its holdings in shares of Astrazeneca PLC by 287,844.0% during the 1st quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock valued at $215,198,000 after acquiring an additional 6,908,257 shares in the last quarter. Federated Investors Inc. PA lifted its holdings in shares of Astrazeneca PLC by 3.6% during the 2nd quarter. Federated Investors Inc. PA now owns 4,484,770 shares of the company’s stock valued at $152,885,000 after acquiring an additional 156,256 shares in the last quarter. Ameriprise Financial Inc. lifted its holdings in shares of Astrazeneca PLC by 5.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,827,262 shares of the company’s stock valued at $96,789,000 after acquiring an additional 157,293 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of Astrazeneca PLC by 38.2% during the 2nd quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after acquiring an additional 662,481 shares in the last quarter. Institutional investors and hedge funds own 14.18% of the company’s stock.

Several research analysts have recently issued reports on the company. BMO Capital Markets set a $38.00 price objective on Astrazeneca PLC and gave the company a “buy” rating in a research note on Tuesday. Leerink Swann upped their price objective on Astrazeneca PLC from $31.00 to $34.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Citigroup Inc raised Astrazeneca PLC to a “buy” rating in a research note on Wednesday, October 18th. Cowen and Company reaffirmed a “hold” rating and issued a $37.00 price objective on shares of Astrazeneca PLC in a research note on Tuesday, October 17th. Finally, Credit Suisse Group raised Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Four research analysts have rated the stock with a sell rating, ten have given a hold rating and fifteen have given a buy rating to the company’s stock. Astrazeneca PLC has an average rating of “Hold” and an average target price of $35.10.

ILLEGAL ACTIVITY WARNING: This story was first reported by American Banking News and is owned by of American Banking News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.americanbankingnews.com/2017/11/04/astrazeneca-plc-target-of-unusually-high-options-trading-azn.html.

About Astrazeneca PLC

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.